Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Mackay, A.V.P.
1982.
Drugs in Psychiatric Practice.
p.
42.
Linden, Robert
Davis, John M.
and
Rubinstein, Joan
1984.
Guidelines for the Use of Psychotropic Drugs.
p.
151.
Nishikawa, Tadashi
Tsuda, Akira
Tanaka, Masatoshi
Hoaki, Yoshio
Koga, Itsuyuki
and
Uchida, Yasunori
1984.
Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine.
Psychopharmacology,
Vol. 82,
Issue. 3,
p.
153.
Nishikawa, Tadashi
Tsuda, Akira
Tanaka, Masatoshi
Koga, Itsuyuki
and
Uchida, Yasunori
1985.
Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers.
Biological Psychiatry,
Vol. 20,
Issue. 11,
p.
1161.
Curson, D. A.
Barnes, T. R. E.
Bamber, R. W.
Platt, S. D.
Hirsch, S. R.
and
Duffy, J. C.
1985.
III. Relapse Postponement or Relapse Prevention? The Implications for Long-term Outcome.
British Journal of Psychiatry,
Vol. 146,
Issue. 5,
p.
474.
Pool, Vaira Eve
and
Elder, S Thomas
1986.
A selected review of the literature and an empirical analysis of drug treatment compliance by schizophrenic patients.
Applied Psychology,
Vol. 35,
Issue. 4,
p.
547.
Möller, H. J.
1987.
Neuroleptika Rückschau 1952–1986, Künftige Entwicklungen.
p.
63.
Kitamura, Toshinori
McGovern, Dermot A.
Imlah, Norman W.
Wiles, David
and
Schiff, Anthony A.
1988.
Plasma levels of fluphenazine and prolactin in psychiatric patients.
European Archives of Psychiatry and Neurological Sciences,
Vol. 237,
Issue. 6,
p.
320.
Kane, John M.
1989.
A Clinical Guide for the Treatment of Schizophrenia.
p.
43.
Nishikawa, Tadashi
Tanaka, Masatoshi
Tsuda, Akira
Koga, Itsuyuki
and
Uchida, Yasunori
1989.
Prophylactic effects of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of timiperone and sulpiride.
Biological Psychiatry,
Vol. 25,
Issue. 7,
p.
861.
Harris, Grant T.
1989.
The relationship between neuroleptic drug dose and the performance of psychiatric patients in a maximum security token economy program.
Journal of Behavior Therapy and Experimental Psychiatry,
Vol. 20,
Issue. 1,
p.
57.
Kane, J. M.
1990.
Treatment programme and long‐term outcome in chronic schizophrenia.
Acta Psychiatrica Scandinavica,
Vol. 82,
Issue. S358,
p.
151.
de Zwaan, Martina
and
Schönbeck, G.
1990.
Schizophrene erkennen, verstehen, behandeln.
Vol. 1,
Issue. ,
p.
105.
Gracia, Rafael I.
Gutierrez, Jose M.
Faraone, Stephen V.
and
Tsuang, Ming T.
1990.
Use of Lorazepam for Increased Anxiety After Neuroleptic Dose Reduction.
Psychiatric Services,
Vol. 41,
Issue. 2,
p.
197.
Kane, John M.
1990.
Recent Advances in Schizophrenia.
p.
257.
Coleman, Tom
1990.
Smokers' Civil Rights.
Psychiatric Services,
Vol. 41,
Issue. 2,
p.
198.
Tegeler, J.
1990.
Thioxanthene.
p.
63.
Möller, H.-J.
1990.
Leitlinien neuroleptischer Therapie.
p.
97.
Müller-Spahn, F.
1990.
Psychopharmaka heute.
p.
129.
Meise, U.
Kurz, M.
Schett, P.
and
Fleischhacker, W. W.
1991.
Fortschritte im Umgang mit schizophrenen Patienten.
Vol. 2,
Issue. ,
p.
145.
eLetters
No eLetters have been published for this article.